The European Patent Office (EPO) has granted a patent for the treatment of heart failure patients with reduced ejection fraction, with oral iron succinate. The patent provides protection in 26 countries and Bio Vitos Pharma AB owns the rights to this patent within the EU excluding the Nordic countries. The clinical trials conducted by DBP show that iron succinate significantly improves iron absorption, iron saturation and iron storages in patients with heart failure and iron deficiency.

Iron succinate is a less expensive alternative to the successful product Ferinject (which ? as the name suggests ? is administered intravenously).

In 2022, the global sales of Ferinject amounted to approximately USD 500 million.